Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.58 |
| ▸ | ESR1 | P03372 | 4/20 | 0.56 |
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CA7 | P43166 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31182 | 0.98 | SNCA (0.59) | SNCAESR1CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL28144301 | 0.96 | SNCA (0.58) | SNCAESR1CA12CA1CA2 | |
| SCHEMBL1679462 | 0.93 | LMNA (0.58) | SNCAESR1CA12CA1CA2 | |
| Paraben SCHEMBL1146606 | 0.91 | SNCA (0.54) | SNCAESR1CA12CA1CA2 | |
| Phenol SCHEMBL28318935 | 0.91 | LMNA (0.60) | SNCAESR1CA12CA1CA2 | |
| SCHEMBL175786 | 0.90 | SNCA (0.67) | SNCAESR1CA12CA1CA2 | |
| SCHEMBL1222875 | 0.89 | SNCA (0.51) | SNCAESR1CA12CA1CA2 | |
| SCHEMBL461801 | 0.85 | SNCA (0.61) | SNCAMEN1KMT2ACYP3A4ALDH1A1 | |
| SCHEMBL17386391 | 0.85 | SNCA (0.61) | SNCAESR1CA12CA1CA2 | |
| Benzyl Alcohol SCHEMBL23391584 | 0.85 | LMNA (0.60) | SNCAESR1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5155808-A | — | — | None | — | — | JP | disclosed |
| US-20230125630-A1 | POLYPHOSPHAZENES, METHODS OF MAKING, AND USES THEREOF | UNIV MARYLAND (US) | 2023-04-27 | — | — | US | disclosed |
| US-11472927-B2 | Polyphosphazenes, methods of making, and uses thereof | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2022-10-18 | — | — | US | disclosed |
| US-20180327550-A1 | POLYPHOSPHAZENES, METHODS OF MAKING, AND USES THEREOF | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2018-11-15 | — | — | US | disclosed |
| EP-3377560-A1 | POLYPHOSPHAZENES, METHODS OF MAKING, AND USES THEREOF | University of Maryland, College Park (US) | 2018-09-26 | — | — | EP | disclosed |
| US-20160377620-A1 | COMBINATION HEPATITIS C VIRUS ANTIGEN AND ANTIBODY DETECTION METHOD | ABBOTT LABORATORIES | 2016-12-29 | — | — | US | disclosed |
| US-9470686-B2 | Combination hepatitis C virus antigen and antibody detection method | ABBOTT LABORATORIES (US) | 2016-10-18 | — | — | US | disclosed |
| EP-2064551-B1 | COMBINATION HEPATITIS C VIRUS ANTIGEN AND ANTIBODY DETECTION METHOD | ABBOTT LAB (US) | 2015-12-09 | — | — | EP | disclosed |
| EP-2910949-A1 | Combination hepatitis C virus antigen and antibody detection method | Abbott Laboratories (US) | 2015-08-26 | — | — | EP | disclosed |
| US-20150177242-A1 | COMBINATION HEPATITIS C VIRUS ANTIGEN AND ANTIBODY DETECTION METHOD | ABBOTT LABORATORIES | 2015-06-25 | — | — | US | disclosed |
| EP-0634016-A4 | ASSAY VERIFICATION CONTROL FOR ANALYTICAL METHODS. | ABBOTT LAB (US) | 1997-06-04 | — | — | EP | disclosed |
| US-5635406-A | Stabilized standards and calibrators containing rapamycin and tacrolimus bound to anti-rapamycin and anti-tacrolimus antibodies | ABBOTT LABORATORIES (US) | 1997-06-03 | — | — | US | disclosed |
| WO-1996041184-A1 | STABILIZED STANDARDS AND CALIBRATORS | ABBOTT LABORATORIES (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0634016-A1 | ASSAY VERIFICATION CONTROL FOR ANALYTICAL METHODS | ABBOTT LABORATORIES (US) | 1995-01-18 | — | — | EP | disclosed |
| WO-1994024568-A1 | STABLE AQUEOUS FK506 STANDARDS | ABBOTT LABORATORIES (US) | 1994-10-27 | — | — | WO | disclosed |
| US-5338684-A | Stable aqueous FK506 standards | ABBOTT LABORATORIES (US) | 1994-08-16 | — | — | US | disclosed |
| US-5266721-A | Process for preparing the pure enantiomers of lifibrol and its alkyl esters | KLINGE PHARMA GMBH (DE) | 1993-11-30 | — | — | US | disclosed |
| US-5266721-A | Process for preparing the pure enantiomers of lifibrol and its alkyl esters | KLINGE PHARMA GMBH (DE) | 1993-11-30 | — | — | US | disclosed |
| WO-1993020443-A1 | ASSAY VERIFICATION CONTROL FOR ANALYTICAL METHODS | ABBOTT LABORATORIES (US) | 1993-10-14 | — | — | WO | disclosed |
| JP-H05155808-A | PRODUCTION OF PURE ENANTIOMER OF 4(4-(4'TERT-BUTYL PHENYL)-2HYDROXYBUTOXY) BENZOIC ACID AND ITS ALKYLESTER | KLINGE PHARM GMBH & CO | 1993-06-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125630-A1 | POLYPHOSPHAZENES, METHODS OF MAKING, AND USES THEREOF | PHOSPHO1, PLCG2, PLCG1 | SNCA 3841/4885ESR1 3224/4885CA12 154/4885 |
| US-20180327550-A1 | POLYPHOSPHAZENES, METHODS OF MAKING, AND USES THEREOF | PHOSPHO1, PLCG2, PLCG1 | SNCA 3841/4885ESR1 3224/4885CA12 154/4885 |
| US-11472927-B2 | Polyphosphazenes, methods of making, and uses thereof | PHOSPHO1, PLCG2, PLCG1 | SNCA 3841/4885ESR1 3224/4885CA12 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.